Nrf2 upregulates the transcription of 3 main target genes in response to SFN and zymosan. by Doumet Georges Helou (7255823)

Variants enriched in an <i>Ae</i>. <i>aegypti</i> cell line <i>(</i>Aag2) have increased fitness in Aag2 cells but decreased fitness in a human cell line (MRC-5). by Chelsea Cereghino (15188341)

Density plots of normalised consumer final power (PC) for the six example networks, shown over decreasing ratios of mean consumer to mean resource potential, . by Natalie Davis (8556036)

“…<p>Each plot shows the density for the normalised consumer final power at = 0.75, 0.5, and 0.25, from left to right, as the ratio decreases due to increased resource flow during the simulation. …”

Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

<i>In vivo</i> HDL protects the heart from IR injury via STAT3 activation. by Sarah Pedretti (703288)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Five compounds significantly decrease MAPK1 phosphorylation in K562 cells. by Pamela Y. Ting (713174)

Effect of specific inhibitors on CYP-mediated CK (50 μM) metabolism in HLMs. by Jian Xiao (253329)

Y86 is critical for SERINC3/5 antagonism by SIVcol Nef. by Dorota Kmiec (5646374)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Physiological characterization of rice <i>m167</i> plants. by Xuexia Wang (3701098)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects: